India: Breaking The Section 3(D) Code

Last Updated: 25 November 2008
Article by Jitender Bhatia

One topic that does not die out is with respect to Section 3(d) of the Indian Patents Act. Most of us have witnessed Section 3(d) objection mocking like a silent spectator under paragraphs 3 or 4 of the First Examination Report. The objection gradually moves up places in the further official actions until it takes all that familiar position under paragraph 1. The question remains – how do we break the 3(d) code?

Section 3 of the Act enumerates inventions that are not patentable. Section 3(d) relates to new forms of known substances. The part of the 'Explanation' corresponding to clause (d) of section 3 - "considered to be the same substance, unless they (i.e., derivatives of known substances) differ significantly in properties with regard to efficacy"- reveals a test of patentability with 'enhanced efficacy' as the criteria.

The present study is aimed to provide possible practical solutions to evade or overcome the objection under Section 3(d). We shall focus on possible strategies that may be employed especially in inventions relating to chemical compounds.

While dealing with objections under Section 3(d), we propose that the following four line strategy:

Line 1 – Resist the objection by laying emphasis on novelty, inventive step and industrial applicability of the invention:

It should be noted that Section 3(d) as worded reads: "The mere discovery of ........". Our aim in the first line of defense is to argue that what is being claimed is not a "mere discovery" but an invention.

According to Webster's Revised Unabridged Dictionary, a discovery has been defined as "The action of discovering; exposure to view; laying open; showing", or "that which is discovered; a thing found out, or for the first time ascertained or recognized, as, the properties of the magnet were".

Going by the same source, an invention has been defined as "the act of finding out or inventing; contrivance or construction of that which has not before existed; or "that which is invented; an original contrivance or construction".

Discovery is finding out something which is already occurring in nature. It may be argued that what is being claimed is not a mere discovery but an invention since it did not exist prior to the date of filing of the Patent application. As an example, fire is a discovery since it always occurred in nature. However, an X salt of rosiglitazone is an invention since it did not exist prior to the date of the invention.

Under Indian Patents Act, an invention has been defined as a novel product or process having inventive step and industrial applicability. You may argue that if something satisfies the said criteria, it should be categorized as an invention rather than a mere discovery under Section 3(d).

Line 2: Response to the First Examination Report:

It is advisable that the best argumentation be presented while the objection is still in its nascent stages. A study of the recent case laws suggests that an objection with respect to Section 3(d) can be overcome provided enhanced therapeutic efficacy is established. The second line aims to utilize this explanation.

If an objection with respect to Section 3(d) is raised in the Examination Report, submit the first response early. An early response would give the Examiner sufficient time to study the response vis-à-vis the objections raised. Also, if the Examiner maintains the said objection, it is apparent that the further official action may be issued earlier. This may provide the applicant sufficient time to submit an additional response.

Further, critically evaluate and resist the objection in the first response. Supplement the response with detailed clinical data evidencing enhanced therapeutic efficacy of the claimed compounds over the prior art compound. To top it all, submit an affidavit from a technical expert verifying enhancement in efficacy at this stage itself.

The question here is - what would be considered as 'substantial improvement' while considering the explanation provided under Section 3(d). While the picture is ambiguous, on most occasions a twenty five to thirty percent improvement in therapeutic efficacy is considered substantial by the Examiners.

Further, of late, it has been observed that the Examiners require clinical data for most if not each of the claimed compounds. Therefore, it is advisable that maximum claimed compounds be tested for therapeutic efficacy in clinical data.

From the recent case laws, you may note that the term efficacy under Section 3(d) is with respect to therapeutic efficacy. The question is what should be the case where enhancement is with respect to aspects like flowability, stability and bulk handling of the compound. Unfortunately, the picture is still ambiguous here. Does it essentially mean that we have reached a dead end?

You may note that most compounds, which are subject matter of inventions, are used in therapy. Let us take an example. I say that my salt A is more stable than the compound of the prior art B. While my salt A is 90% intact after three weeks, the compound of prior art is 50% intact after the same time. The Examiner continues to stress on the enhancement of therapeutic efficacy. What if we conduct an experiment wherein fixed amounts of salt A and compound B are first kept on shelf for 3 weeks and then administered to a patient? If my compound A is stable over the shelf, won't it be more viable at the end of three weeks and therefore more effective therapeutically? Questions like these are yet to be answered.

Line 3 – Revision of the claims:

If the arguments referred in the preceding paragraphs are not acceptable to the Examiner, you may consider revising the claims in accordance with either of the following routes. It has to be noted that the revisions should be supported by the specification and the original set of claims.

Route 1: Direct them to a process of preparation.

Revise the claims by directing them to a process of preparation. Under Indian practice a single application claim is allowable in a Patent application. Therefore, a single compound claim as an application claim of the process may still be allowable.

Route 2: Direct them to a composition

Revise the claims to a composition comprising compound along with other active agents and/or adjuvants. However, please note that Indian practice requires that composition be defined in terms of the requisite ratio/weight percentages of components. You may therefore be required to disclose weight percentages of the components in the main composition claim.

Line 4 – Divisional applications:

Under the Indian Patents Act, an Applicant may file divisional applications under two conditions: on its own motion (suo moto) or to overcome the Examiner's objection with respect to plurality of distinct inventions.

Therefore, if the chances of allowance of the compound claims appear bleak, a divisional application may be submitted. Further, while submitting a divisional application, it is advisable that the subject matter of compound claims be claimed in the divisional application. The parent application may then be allowed to proceed to grant with the secondary process or composition claims.

This approach may help in keeping the compound claims pending, while giving the Applicant additional time to conduct clinical trials and prepare technical affidavits, which may be required during prosecution of the divisional application.

The topic is often discussed and the issue does not seem to die out. While we have endeavored putting together certain possible solutions, there are still others that could be better explored and practiced. All the same the examiners and the applicants should, together, not allow the ambiguity in law to jeopardize the essence of patenting, more so in India where the need for innovation and technology is so progressively vibrant. Well-drafted patents, carefully analyzed laws and well thought decisions could go a long way in safeguarding both public and private interests.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions